Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled XXXX analog (90)Y-DOTATATE: case report.

@entity1 @entity70805 @entity5 @entity2012 @entity977 @entity14103 @entity1943 @entity10759 @entity9045
UNASSIGNED: @entity977 causing @entity2012 are usually macroadenomas at the time of diagnosis, and they can grow aggressively, infiltrating surrounding tissues. @entity5 removal at surgery can lead toward a strong tendency for recurrence, making it necessary to consider a means of treatment other than those currently used such as @entity1943 analogs (SSAs), @entity9045 antagonist, surgical removal, and radiotherapy. The purpose of this paper is to describe a @entity1 diagnosed with an aggressive, @entity5 refractory to medical therapy but ultimately treated with the radiolabeled @entity1943 analog (90)Y-DOTATATE. A 26-year-old male with an invasive macroadenoma of the pituitary gland (5.6 * 2.5 * 3.6 cm) and biochemically confirmed @entity2012 underwent 2 partial @entity5 resections: the first used the transsphenoidal approach and the second used the transcranial method. The @entity1 received SSAs pre- and postoperatively. Because of the progression in @entity977 size, he underwent classic irradiation of the @entity5 (50 Gy). One and a half years later, the @entity1 presented with clinically and biochemically active disease, and the @entity5 size was still 52 mm in diameter (height). Two neurosurgeons disqualified him from further surgical procedures. After confirming the presence of @entity1943 receptors in the @entity977 by using @entity14103 PET/CT, we treated the @entity1 4 times with an SSA bound with (90)Y-DOTATATE. After this treatment, the @entity1 attained partial biochemical remission and a reduction in the @entity5 mass for the first time. Treatment with an SSA bound with @entity70805 may be a promising option for some aggressive @entity10759 when other methods have failed.
